Characterization of Methylation Patterns in Cancer and Non-Cancer cfDNA

Cancer Clinical Trial

Official title:

Characterization of Methylation Patterns in Cancer and Non-Cancer cfDNA, An Observational Multicenter Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04264767
• Other study ID #: PNC-RND-UR-001
• Status: Completed
• Start date: April 17, 2019
• Est. completion date: January 30, 2021

Study information

• Verified date: June 2022
• Source: Nucleix Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Nucleix EpiCheck® tests analyzes the methylation pattern in a panel of DNA methylation biomarkers and determines whether this pattern is consistent with cancer under test or with non-cancer tissue.

This study is being performed as part of the development process of the Pan Cancer EpiCheck test which includes the identification of different methylation profiles in various cancer types and healthy controls.

Description:

The aim of this study is to characterize methylation patterns that will distinguish cancer from normal samples and will be able to recognize the origin of the cancer by collecting cfDNA (circulating free DNA) from blood samples collected from patients with a new diagnosis of cancer and from healthy volunteers who do not have diagnosis or history of cancer. Identifying those methylation patterns may assist in the development of blood test that will be able to detect the presence and the origin of wide range of human cancers

Recruitment information / eligibility

• Status: Completed
• Enrollment: 800
• Est. completion date: January 30, 2021
• Est. primary completion date: January 30, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 22 Years to 80 Years

Eligibility

Inclusion Criteria - Cases:

1. Age = 22 years

2. Subjects who are willing and able to provide written informed consent.

3. Subjects with confirmed diagnosis of cancer (primary or recurrent) at all stages, however did not yet undergo any surgery, chemotherapy, radiation or any other treatment for this cancerous lesion (including, but not limited to systemic therapies). Recent cancer staging should be within 60 days prior to baseline visit.

Exclusion Criteria - Cases:

1. Known prior diagnosis of cancer except of:

1. Fully resected non-melanoma skin cancer

2. History of the original cancer in cases of recurrent disease.

2. Current co-diagnosis of another type of cancer.

3. Currently receiving, or ever received, any of the following therapies to treat their current cancer: surgical management of the cancer beyond that required to establish the cancer diagnosis; local, regional or systemic chemotherapy including chemoembolization; targeted therapy, immunotherapy including cancer vaccines; hormone therapy; or radiation therapy

4. Pregnancy (by self-report)

5. Current febrile illness

6. Acute exacerbation or flare of an inflammatory condition requiring escalation in medical therapy within 14 days prior to blood draw.

7. Recipient of organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant

Inclusion Criteria - Controls:

1. Age 45 to 80 years

2. Subjects who are willing and able to provide written informed consent

Exclusion Criteria - Controls:

1. Known current or prior diagnosis of cancer except of fully resected non-melanoma skin cancer

2. Currently in work-up due to suspicion of cancer of any kind

3. Oral or IV corticosteroid use in past 14 days prior to blood draw

4. Pregnancy (by self-report)

5. Current febrile illness

6. Acute exacerbation or flare of an inflammatory condition requiring escalation in medical therapy within 14 days prior to blood draw.

7. Recipient of organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant

8. Life expectancy < 24 months

Related Conditions & MeSH terms

• Cancer
• Hematologic Neoplasms
• Solid Tumor

Intervention

Procedure:
• Blood collection
Peripheral blood collection via routine venipuncture

Locations

Country	Name	City	State
Israel	Sourasky Medical Center	Tel Aviv
United States	Los Angeles Hematology Oncology Medical Group - Wilson Terrace	Glendale	California
United States	Los Angeles Hematology Oncology Medical Group - Good Samaritan Medical Offices	Los Angeles	California

Sponsors (1)

Lead Sponsor	Collaborator
Nucleix Ltd.

Countries where clinical trial is conducted

United States,  Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To collect blood and urine samples and clinical data in order to characterize methylation patterns that will discriminate cancer and normal (non-cancer) samples and the origin of cancer	To collect blood and urine samples and clinical data in order to characterize methylation patterns that will discriminate cancer and normal (non-cancer) samples and the origin of cancer	72 Months
Primary	To develop a molecular blood test that will be able to detect wide range of human cancers based on change in methylation patterns between cancer and normal samples	To develop a molecular blood test that will be able to detect wide range of human cancers based on change in methylation patterns between cancer and normal samples	72 Months